<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lipid abnormalities in thyroid disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lipid abnormalities in thyroid disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lipid abnormalities in thyroid disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A relationship among hypothyroidism, lipid disorders, and coronary artery disease was first suggested in the 1960s [<a href="#rid1">1</a>]. This was at a time when the diagnosis of hypothyroidism was based upon symptoms and signs, and sometimes serum cholesterol measurements, rather than measurements of serum thyroxine (T4) and thyroid-stimulating hormone (TSH). In some cases, a high serum cholesterol concentration was regarded as evidence for "premyxoedema" in the absence of symptoms of hypothyroidism [<a href="#rid2">2</a>]. How many of these patients in fact had hypothyroidism is not known. While there is no doubt that many hypothyroid patients have abnormal serum lipid concentrations, the increased risk of coronary artery disease seen in hypothyroid patients is likely multifactorial in etiology. (See  <a class="medical medical_review" href="/d/html/7852.html" rel="external">"Cardiovascular effects of hypothyroidism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERT HYPOTHYROIDISM</span><span class="headingEndMark"> — </span>Many hypothyroid patients have high serum concentrations of total cholesterol and low-density lipoprotein (LDL) cholesterol [<a href="#rid3">3</a>], and some have high serum concentrations of triglycerides [<a href="#rid4">4</a>], intermediate-density lipoproteins [<a href="#rid5">5</a>], apolipoprotein A1 [<a href="#rid6">6</a>], and apolipoprotein B [<a href="#rid6">6-8</a>]. (See  <a class="medical medical_review" href="/d/html/4565.html" rel="external">"Lipoprotein classification, metabolism, and role in atherosclerosis"</a>.)</p><p>In one study of 295 hypothyroid patients, the following patterns of serum lipids were noted, using the Frederickson classification [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Type IIa (hypercholesterolemia) – 56 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Type IIb (hypercholesterolemia and hypertriglyceridemia) – 34 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Type IV (hypertriglyceridemia) – 1.5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>No abnormality – 8.5 percent</p><p></p><p>With respect to serum high-density lipoprotein (HDL) cholesterol concentrations, high, normal, or low values have been reported in different series [<a href="#rid10">10,11</a>]. Among the subfractions of HDL cholesterol, it is the HDL2, not HDL3, fraction that may be high in hypothyroidism and normalize during T4 (<a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>) therapy [<a href="#rid8">8,12</a>]. In a study of 18 hypothyroid women after thyroidectomy, HDL cholesterol was higher, but the transfer of esterified and nonesterified cholesterol, triglycerides, and phospholipids was reduced [<a href="#rid13">13</a>].</p><p>The excess risk of coronary heart disease observed with hypothyroidism has been thought to be due, at least in part, to the characteristic lipid abnormalities (including high LDL). However, in a study using nuclear magnetic resonance (NMR) spectroscopy to assess lipid subparticle concentrations, hypothyroid women had a shift toward less atherogenic large LDL, small very low-density lipoprotein (VLDL), and large HDL subparticle sizes [<a href="#rid14">14</a>].</p><p>Overt hypothyroidism is associated with both hepatic and pancreatic steatosis [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Effect of T4 therapy</span><span class="headingEndMark"> — </span>In a meta-analysis, treatment of hypothyroidism (and to a lesser extent subclinical hypothyroidism) resulted in a fall in total, LDL, and HDL cholesterol; triglycerides; apolipoprotein A and B; and lipoprotein(a) [<a href="#rid17">17</a>]. In individual studies, changes in serum lipoprotein(a) concentrations in hypothyroidism and during T4 (<a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>) therapy vary. In some patients, serum lipoprotein(a) concentrations are high and fall during T4 therapy [<a href="#rid7">7,18,19</a>], whereas others have normal values that do not change during therapy [<a href="#rid6">6,8,20,21</a>]. One study found that total cholesterol, triglycerides, LDL cholesterol, apolipoprotein B, and the ratio of apolipoprotein A-I to A-II were elevated in hypothyroid and fell with T4 therapy, while elevated levels of HDL cholesterol and apolipoprotein E did not respond to T4 administration [<a href="#rid22">22</a>].</p><p>An analysis of 19 published studies evaluated the effects of T4 therapy on the serum total cholesterol concentration in patients with overt hypothyroidism [<a href="#rid23">23</a>]. Patients with an initial value of 310 mg/dL (8.0 mmol/L) or less had a mean fall of 46 mg/dL (1.2 mmol/L) during T4 therapy; those with an initial value of more than 310 mg/dL (8.0 mmol/L) had a much greater mean fall of 131 mg/dL (3.4 mmol/L).</p><p>Remnant lipoprotein concentrations (intermediate-density lipoproteins), a predictor of coronary heart disease risk, may also be elevated in overt hypothyroidism with a lowering in response to T4 therapy [<a href="#rid24">24</a>]. The same investigators have reported similar findings in patients with subclinical hypothyroidism. (See <a class="local">'Subclinical hypothyroidism'</a> below.)</p><p>Non-HDL cholesterol (total cholesterol minus HDL cholesterol) was also lowered in both overt and subclinical hypothyroidism after T4 therapy [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>The primary mechanism for hypercholesterolemia in hypothyroidism is accumulation of LDL cholesterol due to a reduction in the number of cell-surface receptors for LDL [<a href="#rid26">26</a>], resulting in decreased catabolism of LDL. A decrease in LDL receptor activity has also been described [<a href="#rid27">27</a>].</p><p>The extent of upregulation of the LDL receptor by T4 therapy varies considerably in patients with different polymorphisms of the LDL receptor gene. In one study, patients homozygous for one specific genotype (-/-) had a fourfold greater reduction in serum cholesterol during T4 therapy than those who were homozygous for a different genotype (+/+) [<a href="#rid28">28</a>].</p><p>Other mechanisms also may affect the serum cholesterol concentration in hypothyroidism:</p><p class="bulletIndent1"><span class="glyph">●</span>LDL oxidation is significantly increased in hypothyroid patients, the degree of which is directly related to the serum LDL cholesterol concentration [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diminished secretion of cholesterol into bile has been demonstrated in hypothyroid rats [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced cholesteryl ester transfer (the net transfer of cholesterol from HDL to LDL and VLDL) in hypothyroidism may minimize the increase in serum LDL cholesterol concentrations [<a href="#rid31">31</a>].</p><p></p><p>A different mechanism, reduced lipoprotein lipase activity, is responsible for the development of hypertriglyceridemia in hypothyroidism [<a href="#rid3">3,32</a>]. The rate of synthesis of triglycerides was normal in one study [<a href="#rid32">32</a>], but increased in another [<a href="#rid33">33</a>].</p><p>Chylomicron remnants accumulate in hypothyroidism and are cleared more rapidly during T4 treatment [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Prevalence of hypothyroidism in patients with hyperlipidemia</span><span class="headingEndMark"> — </span>A separate question is the frequency of hypothyroidism among patients with hypercholesterolemia. In a retrospective study of 8795 patients with a total serum cholesterol of ≥200 mg/dL or LDL cholesterol of at least 160 mg/dL, serum thyroid-stimulating hormone (TSH) was measured in 49 percent [<a href="#rid35">35</a>]. Of these 4349 patients, 3.5 percent (151) had a serum TSH of 5 to 10 mIU/L and 1.7 percent (74) had a TSH greater than 10 mIU/L. In another study of 248 patients referred to a lipid disorders clinic, 2.8 percent had overt hypothyroidism and 4.4 percent had subclinical hypothyroidism [<a href="#rid36">36</a>].</p><p>Thus, all patients with hypercholesterolemia (and hypertriglyceridemia) should be screened for hypothyroidism (and other secondary causes of hyperlipidemia) before being given specific lipid-lowering drug therapy (see  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Candidates for screening'</a> and  <a class="medical medical_review" href="/d/html/4568.html" rel="external">"Secondary causes of dyslipidemia"</a>). If hypothyroidism is present, the patient should be treated for three to four months with T4. If the serum lipid concentrations are not then normal, specific lipid-lowering therapy may be indicated. (See  <a class="medical medical_review" href="/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p>Patients in the latter group presumably have hypothyroidism superimposed upon primary hyperlipidemia. The effect of hypothyroidism varies with the underlying lipid disorder: It can raise serum intermediate-density lipoprotein cholesterol concentrations in patients with "broad beta" disease [<a href="#rid5">5</a>], exacerbate hypercholesterolemia in patients with familial hypercholesterolemia (who have an underlying defect in the LDL receptor) [<a href="#rid37">37</a>], and exacerbate hypertriglyceridemia in patients with familial hypertriglyceridemia [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Hypothyroidism, autoimmunity, and coronary heart disease</span><span class="headingEndMark"> — </span>Coronary heart disease is increased among patients with overt hypothyroidism; however, in addition to abnormal lipid concentrations, diastolic hypertension (often present in hypothyroidism), as well as abnormalities in endothelial function, C-reactive protein, and other parameters, may be contributing factors. (See  <a class="medical medical_review" href="/d/html/7852.html" rel="external">"Cardiovascular effects of hypothyroidism"</a>.)</p><p>In one study, thyroid antibodies were a risk factor for coronary disease independent of serum cholesterol concentrations or the systemic blood pressure [<a href="#rid39">39</a>]. In another study, euthyroid, normocholesterolemic men and postmenopausal women with either antithyroglobulin or antithyroid peroxidase antibodies had high serum lipoprotein(a) concentrations, which may be a risk factor for coronary disease [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/4566.html" rel="external">"Lipoprotein(a)"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">SUBCLINICAL HYPOTHYROIDISM</span><span class="headingEndMark"> — </span>Most patients with subclinical hypothyroidism have normal serum lipid concentrations. However, some have slightly high serum total and low-density lipoprotein (LDL) cholesterol, triglycerides (due to an increase in both very small and very large triglyceride-rich particles), and lipoprotein(a) concentrations [<a href="#rid6">6,23,41-45</a>], whereas serum high-density lipoprotein (HDL) cholesterol concentrations may be low [<a href="#rid41">41,46,47</a>]. In one study, the effect of subclinical hypothyroidism on total and LDL cholesterol was greater in older (age 60 to 69) than younger (age 40 to 49) patients in one study [<a href="#rid48">48</a>].</p><p>Treatment with T4 (<a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>) improves total and LDL cholesterol [<a href="#rid17">17,23,42,43,49</a>]. In a meta-analysis of 12 studies (940 individuals), total cholesterol was reduced on average by 11.2 mg/dL (0.29 mmol/L) and LDL cholesterol by 8.5 mg/dL (0.22 mmol/L) with T4 treatment, but there was no change in HDL cholesterol or triglycerides [<a href="#rid50">50</a>]. The effect of T4 may be more pronounced in those with overt hypercholesterolemia; in one study, as an example, serum LDL cholesterol fell by 36 mg/dL (0.9 mmol/L, p&lt;0.01) in such patients [<a href="#rid51">51</a>].</p><p>The effects of T4 treatment on serum lipoprotein(a) concentrations is variable; in two studies, they declined by as much as 23 percent [<a href="#rid52">52,53</a>], but did not change in another study [<a href="#rid19">19</a>]. Remnant lipoprotein concentrations (intermediate-density lipoproteins), a predictor of coronary heart disease risk, may also be elevated in both overt and subclinical hypothyroidism with a lowering in response to T4 therapy [<a href="#rid54">54</a>]. In one study, the reductions in remnant-like lipoproteins in patients with subclinical hypothyroidism who were treated with T4 were associated with an increase in hepatic lipoprotein lipase, suggesting a possible mechanism for the reduction [<a href="#rid55">55</a>].</p><p>Subclinical hypothyroidism is associated with both hepatic and pancreatic steatosis [<a href="#rid15">15,16</a>]. In addition, coronary heart disease may be increased among patients with subclinical hypothyroidism who have thyroid-stimulating hormone (TSH) values greater than 7 to 10 mIU/L. (See  <a class="medical medical_review" href="/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults", section on 'Cardiovascular disease'</a>.)</p><p>Conversely, there is evidence that hypertriglyceridemia (and obesity) per se may cause an elevation in TSH via a "lipotoxic" effect on the thyroid [<a href="#rid56">56</a>].</p><p>Whether TSH has a direct role in lipid metabolism is currently under investigation. For example, one study supports the hypothesis that TSH may increase PCSK9, which would result in higher LDL cholesterol by increasing LDL receptor degradation [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H8"><span class="h1">HYPERTHYROIDISM</span><span class="headingEndMark"> — </span>Patients with hyperthyroidism have changes in lipid metabolism generally opposite to those described above for hypothyroidism. Serum total, low-density lipoprotein (LDL), very small triglyceride-rich particles, and high-density lipoprotein (HDL) cholesterol concentrations tend to be low [<a href="#rid45">45,58</a>], as do serum apolipoprotein B concentrations [<a href="#rid7">7</a>]. Fatty acid clearance is increased, but lipolysis is increased even more, resulting in high serum fatty acid concentrations [<a href="#rid4">4</a>]. Serum lipoprotein(a) concentrations were low in one study, but did not increase during antithyroid drug therapy [<a href="#rid58">58</a>]. In a meta-analysis, treatment of overt, but not subclinical, hyperthyroidism increased total, LDL, and HDL cholesterol; apolipoprotein A and B; and lipoprotein(a) [<a href="#rid17">17</a>]. In an individual study, radioiodine treatment of grade 2 subclinical hyperthyroidism (TSH &lt;0.2 mIU/L) increased total and LDL cholesterol [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H6582291"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overt hypothyroidism and serum lipids </strong>– Hypothyroid patients have increased serum total and low-density lipoprotein (LDL) cholesterol levels. Many also have high serum triglycerides, intermediate-density lipoproteins, apolipoprotein A1, and apolipoprotein B concentrations. T4 (<a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>) therapy may reduce total and LDL cholesterol, lipoprotein A and B, and intermediate-density lipoprotein concentrations, especially in patients with significant elevations prior to treatment. (See <a class="local">'Overt hypothyroidism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subclinical hypothyroidism and serum lipids</strong> – Similar findings are noted in patients with subclinical hypothyroidism whose thyroid-stimulating hormone (TSH) concentrations are &gt;10 mIU/L. (See  <a class="medical medical_review" href="/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence of hypothyroidism in patients with hyperlipidemia</strong> – Among patients with hyperlipidemia, overt and subclinical hypothyroidism are common. Thus, patients with hypercholesterolemia (and hypertriglyceridemia) should be screened for hypothyroidism (and other secondary causes of hyperlipidemia) before being given specific lipid-lowering drug therapy. (See <a class="local">'Prevalence of hypothyroidism in patients with hyperlipidemia'</a> above and  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Candidates for screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothyroidism and coronary heart disease</strong> – The increased risk of coronary artery disease seen in overtly hypothyroid patients is likely multifactorial due to elevated lipids, diastolic hypertension, elevated C-reactive protein, endothelial dysfunction, and other factors. Coronary heart disease may be increased among patients with subclinical hypothyroidism who have thyroid-stimulating hormone (TSH) values greater than 7 to 10 mIU/L. (See <a class="local">'Hypothyroidism, autoimmunity, and coronary heart disease'</a> above and  <a class="medical medical_review" href="/d/html/7852.html" rel="external">"Cardiovascular effects of hypothyroidism"</a> and  <a class="medical medical_review" href="/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperthyroidism and serum lipids</strong> – Hyperthyroidism is associated with lower levels of total, LDL, and high-density lipoprotein (HDL) cholesterol. (See <a class="local">'Hyperthyroidism'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bastenie PA, Vanhaelst L, Neve P. Coronary-artery disease in hypothyroidism. Lancet 1967; 2:1221.</a></li><li><a class="nounderline abstract_t">Fowler PS, Swale J. Premyxoedema and coronary-artery disease. Lancet 1967; 1:1077.</a></li><li><a class="nounderline abstract_t">Lithell H, Boberg J, Hellsing K, et al. Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase activity in overt and subclinical hypothyroidism: the effect of substitution therapy. Eur J Clin Invest 1981; 11:3.</a></li><li><a class="nounderline abstract_t">Nikkila E, Kekki M. Plasma triglyceride metabolism in thyroid disease. J Clin Invest 1973; 51:203.</a></li><li><a class="nounderline abstract_t">Hazzard WR, Bierman EL. Aggravation of broad- disease (type 3 hyperlipoproteinemia) by hypothyroidism. Arch Intern Med 1972; 130:822.</a></li><li><a class="nounderline abstract_t">Arem R, Escalante DA, Arem N, et al. Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). Metabolism 1995; 44:1559.</a></li><li><a class="nounderline abstract_t">de Bruin TW, van Barlingen H, van Linde-Sibenius Trip M, et al. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab 1993; 76:121.</a></li><li><a class="nounderline abstract_t">Pazos F, Alvarez JJ, Rubiés-Prat J, et al. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab 1995; 80:562.</a></li><li><a class="nounderline abstract_t">O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.</a></li><li><a class="nounderline abstract_t">Muls E, Rosseneu M, Blaton V, et al. Serum lipids and apolipoproteins A-I, A-II and B in primary hypothyroidism before and during treatment. Eur J Clin Invest 1984; 14:12.</a></li><li><a class="nounderline abstract_t">Agdeppa D, Macaron C, Mallik T, Schnuda ND. Plasma high density lipoprotein cholesterol in thyroid disease. J Clin Endocrinol Metab 1979; 49:726.</a></li><li><a class="nounderline abstract_t">Verdugo C, Perrot L, Ponsin G, et al. Time-course of alterations of high density lipoproteins (HDL) during thyroxine administration to hypothyroid women. Eur J Clin Invest 1987; 17:313.</a></li><li><a class="nounderline abstract_t">Sigal GA, Tavoni TM, Silva BMO, et al. Effects of Short-Term Hypothyroidism on the Lipid Transfer to High-Density Lipoprotein and Other Parameters Related to Lipoprotein Metabolism in Patients Submitted to Thyroidectomy for Thyroid Cancer. Thyroid 2019; 29:53.</a></li><li><a class="nounderline abstract_t">Pearce EN, Wilson PW, Yang Q, et al. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort. J Clin Endocrinol Metab 2008; 93:888.</a></li><li><a class="nounderline abstract_t">Elshinshawy S, Elhaddad H, Abdel Alem S, et al. The Interrelation Between Hypothyroidism and Non-alcoholic Fatty Liver Disease, a Cross-sectional Study. J Clin Exp Hepatol 2023; 13:638.</a></li><li><a class="nounderline abstract_t">Bayyigit A, Gokden Y, Onol S, et al. Hypothyroidism and subclinical hypothyroidism are associated with fatty pancreas (Non-Alcoholic Fatty Pancreas Disease). Diabetes Metab Res Rev 2023; :e3720.</a></li><li><a class="nounderline abstract_t">Kotwal A, Cortes T, Genere N, et al. Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Martínez-Triguero ML, Hernández-Mijares A, Nguyen TT, et al. Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clin Proc 1998; 73:837.</a></li><li><a class="nounderline abstract_t">Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10:803.</a></li><li><a class="nounderline abstract_t">Spandrio S, Sleiman I, Scalvini T, et al. Lipoprotein (a) in thyroid dysfunction before and after treatment. Horm Metab Res 1993; 25:586.</a></li><li><a class="nounderline abstract_t">Klausen IC, Nielsen FE, Hegedüs L, et al. Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a). Metabolism 1992; 41:911.</a></li><li><a class="nounderline abstract_t">Jung KY, Ahn HY, Han SK, et al. Association between thyroid function and lipid profiles, apolipoproteins, and high-density lipoprotein function. J Clin Lipidol 2017; 11:1347.</a></li><li><a class="nounderline abstract_t">Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf) 1996; 44:643.</a></li><li><a class="nounderline abstract_t">Ito M, Takamatsu J, Matsuo T, et al. Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement. Clin Endocrinol (Oxf) 2003; 58:621.</a></li><li><a class="nounderline abstract_t">Ito M, Arishima T, Kudo T, et al. Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab 2007; 92:608.</a></li><li><a class="nounderline abstract_t">Thompson GR, Soutar AK, Spengel FA, et al. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci U S A 1981; 78:2591.</a></li><li><a class="nounderline abstract_t">Hoogerbrugge N, Jansen H, Staels B, et al. Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. Metabolism 1996; 45:680.</a></li><li><a class="nounderline abstract_t">Wiseman SA, Powell JT, Humphries SE, Press M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene. J Clin Endocrinol Metab 1993; 77:108.</a></li><li><a class="nounderline abstract_t">Costantini F, Pierdomenico SD, De Cesare D, et al. Effect of thyroid function on LDL oxidation. Arterioscler Thromb Vasc Biol 1998; 18:732.</a></li><li><a class="nounderline abstract_t">FRIEDMAN M, BYERS SO, ROSENMAN RH. Changes in excretion of intestinal cholesterol and sterol digitonides in hyper and hypothyroidism. Circulation 1952; 5:657.</a></li><li><a class="nounderline abstract_t">Ritter MC, Kannan CR, Bagdade JD. The effects of hypothyroidism and replacement therapy on cholesteryl ester transfer. J Clin Endocrinol Metab 1996; 81:797.</a></li><li><a class="nounderline abstract_t">Pykälistö O, Goldberg AP, Brunzell JD. Reversal of decreased human adipose tissue lipoprotein lipase and hypertriglyceridemia after treatment of hypothyroidism. J Clin Endocrinol Metab 1976; 43:591.</a></li><li><a class="nounderline abstract_t">Gjedde S, Gormsen LC, Rungby J, et al. Decreased lipid intermediate levels and lipid oxidation rates despite normal lipolysis in patients with hypothyroidism. Thyroid 2010; 20:843.</a></li><li><a class="nounderline abstract_t">Weintraub M, Grosskopf I, Trostanesky Y, et al. Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. J Clin Endocrinol Metab 1999; 84:2532.</a></li><li><a class="nounderline abstract_t">Willard DL, Leung AM, Pearce EN. Thyroid function testing in patients with newly diagnosed hyperlipidemia. JAMA Intern Med 2014; 174:287.</a></li><li><a class="nounderline abstract_t">Tsimihodimos V, Bairaktari E, Tzallas C, et al. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 1999; 9:365.</a></li><li><a class="nounderline abstract_t">Illingworth DR, McClung MR, Connor WE, Alaupovic P. Familial hypercholesterolaemia and primary hypothyroidism: coexistence of both disorders in a young woman with severe hypercholesterolaemia. Clin Endocrinol (Oxf) 1981; 14:145.</a></li><li><a class="nounderline abstract_t">Chait A, Brunzell JD. Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism 1983; 32:209.</a></li><li><a class="nounderline abstract_t">Tièche M, Lupi GA, Gutzwiller F, et al. Borderline low thyroid function and thyroid autoimmunity. Risk factors for coronary heart disease? Br Heart J 1981; 46:202.</a></li><li><a class="nounderline abstract_t">Lotz H, Salabè GB. Lipoprotein(a) increase associated with thyroid autoimmunity. Eur J Endocrinol 1997; 136:87.</a></li><li><a class="nounderline abstract_t">Kung AW, Pang RW, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol (Oxf) 1995; 43:445.</a></li><li><a class="nounderline abstract_t">Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85:2993.</a></li><li><a class="nounderline abstract_t">Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002; 87:1533.</a></li><li><a class="nounderline abstract_t">Nakajima Y, Yamada M, Akuzawa M, et al. Subclinical hypothyroidism and indices for metabolic syndrome in Japanese women: one-year follow-up study. J Clin Endocrinol Metab 2013; 98:3280.</a></li><li><a class="nounderline abstract_t">Janovsky CCPS, Bittencourt MS, Goulart AC, et al. Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil. Endocrinology 2021; 162.</a></li><li><a class="nounderline abstract_t">Althaus BU, Staub JJ, Ryff-De Lèche A, et al. LDL/HDL-changes in subclinical hypothyroidism: possible risk factors for coronary heart disease. Clin Endocrinol (Oxf) 1988; 28:157.</a></li><li><a class="nounderline abstract_t">Caron P, Calazel C, Parra HJ, et al. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. Clin Endocrinol (Oxf) 1990; 33:519.</a></li><li><a class="nounderline abstract_t">Zhao M, Yang T, Chen L, et al. Subclinical hypothyroidism might worsen the effects of aging on serum lipid profiles: a population-based case-control study. Thyroid 2015; 25:485.</a></li><li><a class="nounderline abstract_t">Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86:4860.</a></li><li><a class="nounderline abstract_t">Li X, Wang Y, Guan Q, et al. The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: A systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf) 2017; 87:1.</a></li><li><a class="nounderline abstract_t">Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol 1998; 138:141.</a></li><li><a class="nounderline abstract_t">Yildirimkaya M, Ozata M, Yilmaz K, et al. Lipoprotein(a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapy. Endocr J 1996; 43:731.</a></li><li><a class="nounderline abstract_t">Ganotakis ES, Mandalaki K, Tampakaki M, et al. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy. Angiology 2003; 54:569.</a></li><li><a class="nounderline abstract_t">Ito M, Takamatsu J, Sasaki I, et al. Disturbed metabolism of remnant lipoproteins in patients with subclinical hypothyroidism. Am J Med 2004; 117:696.</a></li><li><a class="nounderline abstract_t">Brenta G, Berg G, Miksztowicz V, et al. Atherogenic Lipoproteins in Subclinical Hypothyroidism and Their Relationship with Hepatic Lipase Activity: Response to Replacement Treatment with Levothyroxine. Thyroid 2016; 26:365.</a></li><li><a class="nounderline abstract_t">Zhao M, Tang X, Yang T, et al. Lipotoxicity, a potential risk factor for the increasing prevalence of subclinical hypothyroidism? J Clin Endocrinol Metab 2015; 100:1887.</a></li><li><a class="nounderline abstract_t">Gong Y, Ma Y, Ye Z, et al. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression. Metabolism 2017; 76:32.</a></li><li><a class="nounderline abstract_t">Hoppichler F, Sandholzer C, Moncayo R, et al. Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels. Atherosclerosis 1995; 115:65.</a></li><li><a class="nounderline abstract_t">Russo L, Nguyen TNH, Kyrilli A, et al. Metabolic Changes after Radioiodine Correction of Grade 1 and Grade 2 Subclinical Hyperthyroidism. Eur Thyroid J 2021; 10:382.</a></li></ol></div><div id="topicVersionRevision">Topic 7857 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4168694" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Coronary-artery disease in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4164771" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Premyxoedema and coronary-artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6783426" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase activity in overt and subclinical hypothyroidism: the effect of substitution therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Plasma triglyceride metabolism in thyroid disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4343211" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aggravation of broad- disease (type 3 hyperlipoproteinemia) by hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8786724" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8421075" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7852521" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8371604" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hyperlipidemia in patients with primary and secondary hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6421595" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Serum lipids and apolipoproteins A-I, A-II and B in primary hypothyroidism before and during treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/226559" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Plasma high density lipoprotein cholesterol in thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3117568" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Time-course of alterations of high density lipoproteins (HDL) during thyroxine administration to hypothyroid women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30412041" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of Short-Term Hypothyroidism on the Lipid Transfer to High-Density Lipoprotein and Other Parameters Related to Lipoprotein Metabolism in Patients Submitted to Thyroidectomy for Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18073305" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37440948" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Interrelation Between Hypothyroidism and Non-alcoholic Fatty Liver Disease, a Cross-sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37691570" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypothyroidism and subclinical hypothyroidism are associated with fatty pancreas (Non-Alcoholic Fatty Pancreas Disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32954428" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737219" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041458" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8288162" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Lipoprotein (a) in thyroid dysfunction before and after treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386404" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958565" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association between thyroid function and lipid profiles, apolipoproteins, and high-density lipoprotein function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759176" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12699445" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17148561" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6264482" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8637440" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8100826" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9598831" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of thyroid function on LDL oxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14926049" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Changes in excretion of intestinal cholesterol and sterol digitonides in hyper and hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636306" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effects of hypothyroidism and replacement therapy on cholesteryl ester transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/956344" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Reversal of decreased human adipose tissue lipoprotein lipase and hypertriglyceridemia after treatment of hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20615126" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Decreased lipid intermediate levels and lipid oxidation rates despite normal lipolysis in patients with hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10404832" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24217672" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Thyroid function testing in patients with newly diagnosed hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319942" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7261412" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Familial hypercholesterolaemia and primary hypothyroidism: coexistence of both disorders in a young woman with severe hypercholesterolaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6827992" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe hypertriglyceridemia: role of familial and acquired disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7272132" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Borderline low thyroid function and thyroid autoimmunity. Risk factors for coronary heart disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037132" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lipoprotein(a) increase associated with thyroid autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586619" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Elevated serum lipoprotein(a) in subclinical hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999775" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932277" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23737542" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Subclinical hypothyroidism and indices for metabolic syndrome in Japanese women: one-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33165533" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3168304" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : LDL/HDL-changes in subclinical hypothyroidism: possible risk factors for coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2121398" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25780934" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Subclinical hypothyroidism might worsen the effects of aging on serum lipid profiles: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600554" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28342184" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: A systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506856" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9075615" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lipoprotein(a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14565632" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15501208" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Disturbed metabolism of remnant lipoproteins in patients with subclinical hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26839156" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Atherogenic Lipoproteins in Subclinical Hypothyroidism and Their Relationship with Hepatic Lipase Activity: Response to Replacement Treatment with Levothyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25742513" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lipotoxicity, a potential risk factor for the increasing prevalence of subclinical hypothyroidism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987238" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7669088" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34540708" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Metabolic Changes after Radioiodine Correction of Grade 1 and Grade 2 Subclinical Hyperthyroidism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
